Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Karuna Therapeutics, Inc.

At Karuna, our purpose is to create and deliver transformative medicines for people living with psychiatric and neurological conditions. 
 
Through the cultivation of our deep expertise in neuroscience, and inventive thinking around drug discovery and development, we are advancing a pipeline of novel medicines with the goal of providing a meaningful difference in the lives of those affected by these conditions.
 
Our culture is defined by our passion to serve those affected by mental illness. We are purpose-driven and intentional. We know impactful innovations don’t come easy, but are borne from passion and hard work. Together, we are working toward a goal bigger than ourselves.
 
We invite you to join us on LinkedIn and Twitter (@KarunaTx) to stay up to date on our work.

Eventide

Fidelity

Fidelity Management and Research Company

Alexandria Venture Investments

Sands Capital Ventures

Sofinnova Investments

ARCH Venture Partners

Partner Fund Management

Pivotal bioVenture Partners

PureTech Health

Wellcome Trust

Karuna Therapeutics

Today on #February11, we join others around the globe to celebrate International Day of Women and Girls in Science. We especially want to recognize the brilliant women in science on our team. Their leadership and dedication are helping us push the boundaries of innovation in neuroscience, and the best is yet to come! #EquityinScience

Bebe Moore Campbell was a fearless mental health advocate and literary trailblazer who used her words and platform to address the impacts of racism, mental health, culture, and community. This #BlackHistoryMonth, we honor and remember her legacy as well as other Black pioneers who helped shape the #MentalHealth landscape. Learn more about their contributions: https://lnkd.in/dPDdCfR

Schizophrenia is a brain disorder that distorts the way a person thinks, feels, and behaves. While current antipsychotic therapies can help treat some symptoms, such as hallucinations and delusions, they may not fully address symptoms such as memory impairment, decision-making, and the ability to enjoy life – leading to low treatment adherence. Learn more about our commitment to addressing these needs: https://lnkd.in/gmN8ykmx 

Signs and symptoms of #schizophrenia are not “one size fits all.” Schizophrenia symptoms can differ from person to person, but they generally fall into three categories. Learn more about them here: https://lnkd.in/gmN8ykmx 

Wishing you #HappyHolidays from all of us at Karuna! May you find peace and enjoy the company of your loved ones during this season. 

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover					0.07 -	0.01 86.95%	0.00 94.65%
cash conversion cycle							8.32K -
cash per share	0.26 -	8.33 3,083.29%	32.56 290.91%	12.19 62.57%	16.95 39.09%	35.54 109.63%	34.17 3.86%
company equity multiplier	-0.16 -	1.01 734.13%	1.01 0.19%	1.03 1.75%	1.05 2.48%	1.03 1.73%	1.07 3.14%
days of inventory outstanding							7.04K -
days of payables outstanding							1.46K -
days of sales outstanding					17.28 -	1.96 88.68%	2.73K 139,717.86%
dividend yield
ebit per revenue					-3.89 -	-27.23 599.77%	-756.54 2,678.04%
ebt per ebit	1.26 -	1.21 3.84%	0.97 19.78%	0.95 1.46%	1.00 4.78%	0.95 5.06%	0.88 7.79%
effective tax rate	-0.19 -	0.02 112.32%	-0.02 184.34%	-0.00 96.89%	-0.00 93.35%	-0.01 12,261.68%	-0.00 70.00%
enterprise value multiple	-32.94 -	-9.12 72.30%	-16.14 76.95%	-38.48 138.35%	-25.27 34.32%	-20.62 18.42%	-23.38 13.41%
fixed asset turnover					3.87 -	1.35 65.12%	0.03 97.64%
free cash flow per share	-0.54 -	-1.43 162.20%	-2.60 81.84%	-2.66 2.38%	-3.57 34.25%	-7.24 102.88%	-10.52 45.32%
gross profit margin					1 -	1 0%	-1.60 260.09%
interest coverage	-4.10 -	-5.62 36.87%	-48.05 755.32%			-20.43 -
inventory turnover							0.05 -
long term debt to capitalization	-0.42 -	0.00 100.26%	0.00 65.44%	0.01 1,304.87%	0.01 94.39%	0.00 74.32%	0.01 304.78%
net income per ebt	1 -	1 0%	1.02 2.02%	1.00 1.92%	1.00 0.06%	1.01 0.51%	1.00 0.36%
net profit margin					-3.89 -	-25.98 567.76%	-663.12 2,452.54%
operating cash flow per share	-0.54 -	-1.42 160.81%	-2.59 82.72%	-2.64 2.15%	-3.46 31.06%	-7.21 108.23%	-10.44 44.81%
operating cycle							9.78K -
operating profit margin					-3.89 -	-27.23 599.77%	-756.54 2,678.04%
payables turnover							0.25 -
pretax profit margin					-3.89 -	-25.85 564.37%	-662.09 2,461.75%
price fair value	-11.11 -	2.38 121.37%	2.31 2.73%	7.93 243.07%	7.60 4.08%	5.52 27.42%	9.33 69.01%
receivables turnover					21.12 -	186.61 783.49%	0.13 99.93%
return on assets	-2.83 -	-0.19 93.32%	-0.11 39.75%	-0.20 72.84%	-0.27 38.19%	-0.24 12.84%	-0.32 36.63%
return on capital employed	0.51 -	-0.16 130.90%	-0.12 26.46%	-0.21 81.05%	-0.28 34.51%	-0.26 9.52%	-0.39 52.12%
return on equity	0.45 -	-0.19 142.38%	-0.12 39.86%	-0.20 75.87%	-0.29 41.62%	-0.25 14.34%	-0.35 40.92%
total debt to capitalization	-6.82 -	0.00 100.02%	0.00 52.08%	0.01 1,374.16%	0.01 87.35%	0.00 68.02%	0.01 178.87%

COM:KARUNATX

Karuna Therapeutics, Inc.

Last Close

329.74

15/03 20:00

Market Cap

12.60B

Beta: -

Volume Today

1.28M

Avg: -

Preview